Table 1.
Number of studies excluded at the second-pass screening (full citations)
| Exclusion reason | Number of studies |
| Review | 16 |
| Animal/in vitro | 7 |
| Disease | 205 |
| Study design | 6 |
| Intervention | 8 |
| Publications with no rFVIIa effectiveness dataa | 9 |
| No SGA for AH | 8 |
| Non-English | 1 |
| No extractable data | 5 |
| Limited data (fewer than 10 patients) | 9 |
| Exclusion reason | Explanation |
| Review/editorial | If a publication is a review or an editorial/commentary, it was excluded using the ‘Review/editorial’ exclusion criterion |
| Animal/in vitro | Non-clinical studies, e.g. studies in animals or in vitro systems, were excluded using the ‘Animal/In vitro’ exclusion criterion |
| Disease | Patients with acquired haemophilia were of interest for this review; if the patient population was different from the population of interest (e.g. CHwI patients), the publication was excluded using the ‘Disease’ exclusion criterion |
| Intervention | Studies investigating therapy other than rFVIIa were not included in this review and were excluded using the ‘intervention’ exclusion criterion |
| No sub-group (SGA) for AH | Studies enrolling mixed populations (such as CHwI + AH) but not reporting separate data for AH patients were excluded using the ‘No SGA for AH’ exclusion criterion |
| No extractable data | Full-text publications in which there were no data pertaining to the haemostatic effectiveness of rFVIIa were excluded using the ‘No extractable data’ exclusion criterion |
| Language/non-English | Only studies with the full-text publication written in English were included in the review. Studies written in a non-English language were excluded using the ‘Non-English’ exclusion criterion |
| CA with limited data | Conference abstracts with no data for rFVIIa dosing or effectiveness were excluded using the ‘CA with limited data’ exclusion criterion |
| Limited data (publications including fewer than 10 eligible patients) | Studies that included fewer than 10 patients of interest (AH treated with rFVIIa) were excluded using the ‘Limited data (publications including fewer than 10 eligible patients)’ exclusion criterion |
AH, acquired haemophilia; CA, conference abstracts; CHwI, congenital haemophilia with inhibitors; rFVIIa, recombinant factor VIIa; SGA, sub-group analysis
aExclusion reason in PRISMA: CA with limited data